Table 4.
QoL | Total sample | p | Urban (n = 82) | p | Rural (n = 71) | p | |||
---|---|---|---|---|---|---|---|---|---|
≤p75 | >p75 | ≤p75 | >p75 | ≤p75 | >p75 | ||||
PF | 52.889 ± 4.83 | 51.037 ± 5.99 | 0.039a | 53.584 ± 4.69 | 52.194 ± 3.90 | 0.039a | 52.184 ± 4.90 | 48.829 ± 8.53 | 0.223a |
RP | 49.694 ± 5.99 | 47.125 ± 6.79 | 0.059a | 50.530 ± 5.68 | 46.405 ± 7.34 | 0.027a | 48.844 ± 6.21 | 48.502 ± 5.66 | 0.797a |
BP | 44.032 ± 11.26 | 38.885 ± 6.77 | 0.014b | 46.331 ± 9.84 | 39.966 ± 5.65 | 0.006b | 41.694 ± 12.19 | 36.821 ± 8.44 | 0.209b |
GH | 47.305 ± 9.13 | 41.310 ± 8.06 | <0.001b | 49.471 ± 9.34 | 41.111 ± 8.45 | <0.001b | 45.102 ± 8.43 | 41.690 ± 7.64 | 0.216b |
VT | 47.401 ± 9.16 | 43.11 ± 7.45 | 0.015b | 47.943 ± 9.48 | 43.705 ± 8.05 | 0.071b | 46.849 ± 8.89 | 41.980 ± 6.35 | 0.088b |
SF | 43.341 ± 10.12 | 36.730 ± 9.24 | 0.003a | 44.876 ± 9.80 | 38.177 ± 9.11 | 0.007b | 41.781 ± 10.29 | 33.969 ± 9.29 | 0.065a |
RE | 48.928 ± 6.53 | 45.019 ± 7.01 | 0.005a | 48.756 ± 6.29 | 44.249 ± 7.92 | 0.009b | 49.103 ± 6.81 | 46.488 ± 4.82 | 0.130a |
MH | 44.926 ± 9.823 | 40.892 ± 9.63 | 0.039b | 45.993 ± 11.06 | 40.966 ± 10.83 | 0.075b | 43.841 ± 8.35 | 40.750 ± 7.27 | 0.254a |
PCSc | 49.851 ± 5.99 | 46.600 ± 4.67 | 0.007a | 51.511 ± 5.52 | 47.269 ± 4.061 | 0.002b | 48.163 ± 5.99 | 45.324 ± 5.71 | 0.301a |
MCSc | 44.665 ± 9.38 | 39.55 ± 8.97 | 0.010a | 45.128 ± 9.70 | 39.510 ± 10.32 | 0.027b | 44.194 ± 9.09 | 39.653 ± 6.05 | 0.116b |
Data presented in mean ± SD; >p75, symptoms of MSD in more than six regions in the last 12 months; QoL, quality of life; PF, physical functioning; RP, role limitations due to physical problems; BP, body pain; GH, general health perception; VT, vitality; SF, social functioning; RE, role limitations due to emotional problems; MH, mental health; PCS, physical component summary; MCS, mental component summary.
Mann–Whitney test.
t-test. p < 0.05.
PCS and MCS score grouped on 50th percentile.